Efficacy and tolerability of pregabalin in partial epilepsy

References

• Dworkin RHP, Corbin AEM, Young JPJ et al. Pregabalin for the treatment of posttherpetic neuralgia: a randomized, placebo-controlled trial. Neurology60, 1274–1283 (2003).
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Gálvez R, Cherry DA et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with postherpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain109, 26–35 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain110, 628–638 (2004).
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain6, 253–260 (2005).
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arth. Rheumatol.52, 1264–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol.23, 240–249 (2003).
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder a placebo-controlled, multicenter study. J. Clin. Psychopharmacol.24, 141–149 (2004).
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol.25, 151–158 (2005).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie M. Effectiveness of first antiepileptic drug. Epilepsia42(10), 1255–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie M. Early identification of refractory epilepsy. N. Engl. J. Med.342, 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregbalin pharmacology and its relevance to clinical practice. Epilepsia45(Suppl. 6), 13–18 (2004).
   PubMed Web of Science ®Google Scholar
• Yuen PW, Kanter GD, Taylor CP, Vartanian MG. Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant. Bioorg. Med. Chem. Lett.4, 823–826 (2003).
   Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (α2-δ) subunit as a target for antiepileptic drug discovery. Epilepsy Res.73, 137–150 (2007).
   PubMed Web of Science ®Google Scholar
• Silverman RB, Andruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG. G. 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. J. Med. Chem.34, 2295–2298 (1991).
   PubMed Web of Science ®Google Scholar
• Errante LD, Petroff OAC. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure12, 300–306 (2003).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res.51(1–2), 31–71 (2002).
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem.271, 5768–5776 (1996).
   PubMed Web of Science ®Google Scholar
• Sills JG. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol.6, 108–113 (2006).
   PubMedGoogle Scholar
• Millan MJ. The neurobiology and control of anxious states. Prog. Neurobiol.70, 83–244 (2003).
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther.295, 1086–1093 (2000).
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain93, 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology42, 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of α2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry65(8), 1033–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RSG. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro.Eur. J. Neurosci.20, 1566–1576 (2004).
   PubMed Web of Science ®Google Scholar
• Coderre, TJ, Kumar N, Lefebvre CD, Yu JSC. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J. Neurochem.94, 1131–1139 (2005).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain105, 133–144 (2003).
   PubMed Web of Science ®Google Scholar
• Bian F, Li Z, Offord JD et al. Calcium channel α2–δ Type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in α2-δ Type 1 genetically modified mice. Brain Res.1075, 68–80 (2006).
   PubMed Web of Science ®Google Scholar
• Field MJ, Cox PJ, Stott E et al. Identification of the α2-δ-1 subunit of voltage dependent calcium channels as a novel molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl Acad. Sci. USA103, 17537–17542 (2006).
   PubMed Web of Science ®Google Scholar
• Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia47(5), 813–819 (2006).
   PubMed Web of Science ®Google Scholar
• Huang CW, Huang CC, Wu SN. The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived H19-7 cells. Epilepsia47(4), 720–726 (2006).
   PubMedGoogle Scholar
• Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J. Pharmacol. Exp. Ther.313, 1406–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res.10, 276–281 (1993).
   PubMed Web of Science ®Google Scholar
• Radulovic LL, Taylor CP, Walker RM. The preclinical pharmacology, pharmacokinetics and toxicology of gabapentin. Med. Actual.31, 597–611(1995).
   Google Scholar
• Bockbrader HN, Hunt T, Strand JC, Posvar EL, Sedman A. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase 1 studies. Neurology54(Suppl. 3), A421 (2000).
   PubMed Web of Science ®Google Scholar
• Kugler AR, Robbins JL, Strand JC et al. Pregabalin overview: a novel CNS-active compound with anticonvulsant activity. Poster presented at: The Annual Meeting of the American Epilepsy Society, Seattle, WA, USA, 6–11 December 2002.
   Google Scholar
• Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther. Drug Monit.27, 451–456 (2005).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia46(9), 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol.43, 277–283 (2003).
   PubMed Web of Science ®Google Scholar
• Corrigan BW, Pool WF, Posvar EL. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin. Pharmacol. Ther.69, P18 (2001).
   Web of Science ®Google Scholar
• Loescher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res.2, 145–181 (1988).
   PubMedGoogle Scholar
• Vartanian MG, Radulovic LL, Kinsora JJ et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res.68, 189–205 (2006).
   PubMed Web of Science ®Google Scholar
• Andre VV, Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia44, 893–903 (2003).
   PubMed Web of Science ®Google Scholar
• French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology60, 1631–1637(2003).
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose–response study in adults with partial seizures. Epilepsia45, 20–27 (2004).
   PubMed Web of Science ®Google Scholar
• Beydoun A, Uthman BM, Kugler AR et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology64, 475–480 (2005).
   PubMed Web of Science ®Google Scholar
• Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia46(12), 1926–1936 (2005).
   PubMed Web of Science ®Google Scholar
• Carreño M, Maestro I, Molins A et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure16(8), 709–712 (2007).
   PubMed Web of Science ®Google Scholar
• Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin. Proc.82(1), 40–47 (2007).
   PubMed Web of Science ®Google Scholar
• Ortinski P, Kimford JM. Cognitive side effects of antiepileptic drugs. Epilepsy Behav.5, 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav.9(3), 424–431 (2006).
   PubMed Web of Science ®Google Scholar
• Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia42(6), 790–792 (2001).
   PubMed Web of Science ®Google Scholar
• Heckmann JG, Ulrich K, Dütsch M, Neundörfer B. Pregabalin associated asterixis. Am. J. Phys. Med. Rehabil.84(9), 724 (2005).
   PubMed Web of Science ®Google Scholar
• Hitiris N, Barrett JA, Brodie MJ. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav.8, 418–421(2006).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res.47, 17–25 (2001).
   PubMedGoogle Scholar
• Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol.28(2), 72–78 (2005).
   PubMed Web of Science ®Google Scholar
• Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia48(7), 1303–1307 (2007).
   PubMed Web of Science ®Google Scholar